

## Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization

10-13 March 2025

### DECLARATION OF INTERESTS

All 15 SAGE members participating in the meeting updated their declaration of interest ahead of the meeting. 12 SAGE members reported relevant interests. All SAGE members can participate in the **discussion** at all sessions. Anthony Scott was asked to recuse himself from the **recommendation-making** on fractional dose PCV. Rebecca Grais was asked to recuse herself from the **recommendation-making** on the multi-age cohort and fractional dose PCV. Kim Mulholland was asked to recuse himself from the **recommendation-making** in relation to reduced PCV dosing schedules. Shabir Madhi was asked to recuse himself from the **recommendation-making** in relation to the PCV session. Cristiana Toscano was asked to recuse herself from the **recommendation-making** related to the varicella and herpes zoster session.

All the reported relevant interests are summarized below:

#### SAGE Members

##### Rebecca Grais

- Serves as a Scientific Advisory Committee member of the Coalition for Epidemic Preparedness Innovations (CEPI). This interest was perceived as non-personal, non-specific and financially insignificant\*.
- Serves as a member at Institut Pasteur Dakar, Manufacturing in Africa for Disease Immunization and Building Autonomy (MADIBA) Project Steering Committee. This interest was perceived as non-personal, non-specific and financially insignificant\*.
- Served until 2023 as a Data and Safety Monitoring Board (DSMB) member on Serum Institute of India for yellow fever vaccine. This interest was perceived as non-personal, non-specific and financially insignificant\*.
- Served until December 2022 as sponsor of fractional dose of Pneumococcal Conjugate Vaccine (PCV), phase IV trial, funded by European & Developing Countries Clinical Trials Partnership (EDCTP). This interest was perceived as non-personal, specific and financially significant\*.

- Serves as a member of the advisory board of MMGH Consulting. This interest was perceived as non-personal, non-specific and financially insignificant\*.
- Served until 2023 as a DSMB member on Scandinavian Bio Pharma/EDCTP. This interest was perceived as non-personal, non-specific and financially insignificant\*.
- Served as sponsor of fractional dose yellow fever, phase IV until 2022, funded by Wellcome trust, and the Médecins Sans Frontières (MSF) foundation. This interest was perceived as non-personal, non-specific and financially insignificant\*.
- Served until November 2022 as site investigator for effectiveness of Ebola vaccine, Phase II/III, funded by the Coalition for Epidemic Preparedness Innovations (CEPI). This interest was perceived as non-personal, non-specific and financially insignificant\*.
- Served in 2023 on the International Vaccine Institute (IVI) Expert Panel on Hepatitis E vaccine in pregnant women. This interest was perceived as non-personal, specific and financially insignificant\*.

### **Gabriel Leung**

- Served on the advisory panel on COVID-19 Vaccines until 2024, Government of Hong Kong SAR. This interest was perceived as non-personal, non-specific and financially insignificant\*.
- Serves on the Wellcome Trust's Board of Governors. This interest was perceived as non-personal, specific and financially insignificant\*.

### **Saad Omer**

- Serves as a member for Food and Drug Administration Center for Biologics Evaluation and Research, Vaccines and Related Biological Products Advisory Committee. This interest was perceived as non-personal, non-specific and financially insignificant\*.
- Served until 2024 as a member on the Board of Trustees of the Sabin Vaccine Institute. This interest was perceived as non-personal, non-specific and financially insignificant\*.
- Serves as a member on the Gavi Board. This interest was perceived as non-personal, non-specific and financially insignificant\*.

- Served until 2023 as a member on the Gavi Programme and Policy Committee. This interest was perceived as non-personal, non-specific and financially insignificant\*.
- Served until 2023 on the Lancet Commission on Vaccines in the USA. This interest was perceived as non-personal, non-specific and financially insignificant\*.
- Served until 2020 on WHO Group B streptococcus (GBS) Value Proposition Technical Working Group. This interest was perceived as non-personal, non-specific and financially insignificant\*.
- Served until 2023 on WHO Expert Steering Committee on Safety Surveillance in Pregnancy in low- and middle-income countries. This interest was perceived as non-personal, non-specific and financially insignificant\*.
- Served until 2024 on WHO Technical Advisory Group on Behavioral Insights and Sciences for Health. This interest was perceived as non-personal, non-specific and financially insignificant\*.
- Served until 2022 as member of the Rockefeller Foundation Global Immunization Initiative (GVI) Advisory Council.
- Affiliation to the Office of Evaluation Sciences (White House Social and Behavioral Sciences Team) until 2021. This interest was perceived as non-personal, non-specific and financially insignificant\*.
- Served until 2021 as a member for National Academies of Sciences, Engineering, and Medicine, Committee on Equitable Allocation of Vaccines for the Novel Coronavirus. This interest was perceived as non-personal, specific and financially insignificant\*.
- Served until 2019 as supervisor-lead for P3-MumBubVax clinical trials. This interest was perceived as non-personal, non-specific and financially insignificant\*.
- Served until 2022 as a consultant for Bill & Melinda Gates Foundation for pooled analysis for three maternal influenza vaccines. This interest was perceived as personal, non-specific and financially significant\*.
- Served until 2023 as principal investigator in the research project funded by Facebook, on evaluating vaccine acceptance messages using social media, this interest was perceived as personal, non-specific and financially significant\*.
- Served as faculty in the Coursera course digital media for health outcome, funded by META. The funding ended in 2024. this interest was perceived as non-personal, non-specific and financially significant\*

- Served until 2022 as a member in Rockefeller's global immunization initiative advisory council to advise them on vaccine acceptance initiatives. This interest was perceived as non-personal, non-specific and financially significant\*.
- Served until 2022 as a faculty on Medscape Steering Committee for the COVID-19 Vaccination Education Center. This interest was perceived as personal, specific and financially significant\*.
- Served until 2021 as a member of national academies of sciences, engineering, and medicine rapid expert consultation (REC) on building vaccine confidence in COVID-19 vaccines. This interest was perceived as non-personal, specific and financially insignificant\*.
- Served until 2021 as a member of national academies of sciences, engineering, and medicine, committee on addressing issues of vaccine distribution and supply chains to advance pandemic and seasonal influenza preparedness and response. This interest was perceived as non-personal, non-specific and financially insignificant\*.
- Served until 2021 as a member of the WHO measuring behavioural and social drivers of vaccination working group. This interest was perceived as non-personal, non-specific and financially insignificant\*.
- Served until 2021 as chair of WHO, global advisory committee on vaccine safety working group on COVID-19 vaccine safety preparedness. This interest was perceived as non-personal, specific and financially insignificant\*.
- He has a pending patent for a machine and technology for a point of care polypill machine to deliver multiple drugs in a single capsule. This interest was perceived as non-personal, non-specific and financially insignificant\*.

### **Cristiana Toscano**

- Served on the Pan American Health Organization (PAHO) Technical Advisory Group until 2024. This interest was perceived as non-personal, non-specific and financially insignificant\*.
- Serves as a member in Brazilian National Immunization Technical Advisory Group (NITAG). This interest was perceived as non-personal, non-specific and financially insignificant\*.
- Serves as a member of the Advisory group of experts for Fiocruz on COVID-19 vaccine development. This interest was perceived as non-personal, non-specific and financially insignificant\*.

- Her institution receives funding from PAHO to provide technical support to evaluate COVID-19 vaccine impact and effectiveness in Latin American Countries. This interest was perceived as non-personal, non-specific and financially significant\*.
- Her institution received funding until 2023 from Results for Development (R4D) to support to support for implementing and evaluating a capacity building program for immunization team in Angola. This interest was perceived as non-personal, non-specific and financially significant\*.
- Her institution receives funding from Results for Development (R4D) to support to support for implementing and evaluating a capacity building program for immunization team in São Tomé e Príncipe. This interest was perceived as non-personal, non-specific and financially significant\*.
- Her institution received research project to evaluate cost of zoster in Brazil and resource utilization in the healthcare system from GSK until 2024. This interest was perceived as non-personal, specific and financially significant\*.
- Her institution received funding from the Pan American Health Organization (PAHO) to provide technical support to research Project on PCV Impact in Latin America until 2024. This interest was perceived as non-personal, specific and financially significant\*.
- Her institution received research support from CNPq – the Brazilian National Council for Technological Research until 2024 for COVID epidemiology and modelling research to support decision making during the pandemic. This interest was perceived as non-personal, non-specific and financially significant\*.
- Her institution received funding from Gavi and R4 for capacity building activities to immunization teams in lusophone countries in Africa transitioning from Gavi support, and linked collaborative learning network on immunization supported by Gavi, until 2024. This interest was perceived as non-personal, non-specific and financially significant\*.

### **Shabir Madhi**

- Serves as a member of RIGHT Foundation Scientific Advisory Board. This interest was assessed as non-personal, non-specific and financially insignificant\*.
- Serves as a member of LeDuq Foundation Scientific Advisory Board on Streptococcus Group A Vaccines. This interest was assessed as non-personal, non-specific and financially insignificant\*.

- Serves as a member of Bavarian Nordic Mpox vaccine DSMB. This interest was assessed as personal, specific and financially insignificant\*.
- Serves as a member of the South African NITAG. This interest was assessed as non-personal, non-specific and financially insignificant\*.
- Serves as an advisor to GSK on a Pneumococcal vaccine currently under development. This interest was assessed as non-personal, specific and financially insignificant\*.
- His institution received the grants from Pfizer on Respiratory syncytial virus (RSV) vaccines. This interest was assessed as non-personal, non-specific and financially insignificant\*.
- Serves as a national principal investigator on RSV vaccines, funded through Pfizer and the Gates Foundation. This interest was assessed as non-personal, non-specific and financially significant\*.
- Serves as a national principal investigator on RSV monoclonal antibody study, funded through AstraZeneca. This interest was assessed as non-personal, non-specific and financially significant\*.
- Serves as national principal investigator to conduct studies on GBS vaccine funded through Pfizer, Minervax, BMGF and Inventprise. This interest was assessed as personal, non-specific and financially significant\*.
- Served as national principal investigator on COVID-19 vaccines until 2023, funded through the Gates Foundation, Novavax and Gritstone. This interest was assessed as personal, nonspecific and financially significant\*.
- His institution received research support from Gates Foundation for RSV, GBS and Klebsiella pneumoniae. This interest was assessed as personal, non-specific and financially significant\*.
- His institution received in 2022 grants for GSK symposium on Pneumococcus viruses. This interest was assessed as non-personal, specific and financially insignificant\*.
- His institution received grants from MSD until 2022 for the study of Pneumococcal conjugate vaccine. This interest was assessed as non-personal, non-specific and financially insignificant\*.
- Served as member of CEPI's Portfolio Strategy and Management Board, until 2022. This interest was assessed as non-personal, non-specific and financially insignificant\*.

- Served until 2024 as a member of the BMGF global health scientific advisory committee. This interest was assessed as non-personal, non-specific and financially insignificant\*.
- Served as principal investigator until 2023 on RSV and COVID-19 studies, funded through Novavax. This interest was assessed as non-personal, non-specific and financially significant\*.
- Served as principal investigator until 2022 on RSV monoclonal antibody study, funded through Medimmune/AstraZeneca. This interest was assessed as non-personal, non-specific and financially significant\*.
- His institution received until 2022 a research grant from Pfizer related to GBS. This interest was assessed as non-personal, non-specific and financially significant\*.

### **Kim Mulholland**

- Served until 2022 as Novavax DSMB for COVID-19 vaccine trials in Australia and South Africa. This interest was perceived as non-personal, non-specific and financially insignificant\*
- Serves as principal investigator of a trial of reduced dose number schedules of Pneumosil in Viet Nam, funded by the Gavi Alliance and BMGF. This interest was assessed as non-personal, specific and financially significant\*
- Serves as co-principal investigator on a Human papillomavirus (HPV) vaccine trial in Viet Nam, funded by UKRI. This interest was assessed as non-personal, non-specific and financially significant\*
- Serves as principal investigator for a PCV introduction study in Mongolia funded by the Gavi. This interest was assessed as non-personal, specific, and financially significant\*.
- Serves as co-investigator on a study of the effectiveness of typhoid conjugate vaccine in Fiji, funded by Korea philanthropy. This interest was assessed as non-personal, non-specific and financially significant\*.
- Serves as principal investigator on a COVID-19 trial in Mongolia, Indonesia, Australia, funded by CEPI. This interest was assessed as non- personal, non-specific and financially significant\*.
- Serves as principal investigator on a study of HPV introduction evaluation in Ethiopia, funded by UK Research and Innovation (UKRI) and BMGF. This interest was assessed as non- personal, non-specific and financially significant\*.

- Serves as investigator on an evaluation of PCV schedules in Nha Trang in Vietnam funded by the BMGF. This interest was assessed as non- personal, specific and financially significant\*.
- Serves as as principal investigator on HPV detection in young women 5 years following the 4-valent HPV vaccine in Mongolia funded by Australian embassy in Mongolia. This interest was assessed as non- personal, non- specific and financially insignificant\*.
- Serves as a member on International Society of Pneumonia and Pneumococcal Diseases (ISPPD) board. This interest was perceived as personal, non-specific and financially insignificant \*.
- Served as principal investigator until 2023 on a study of HPV vaccination of female sex workers in Viet Nam, funded by UKRI. This interest was assessed as non- personal, non- specific and financially significant\*.
- Served until 2022 as principal investigator on the evaluation of the impact of PCV in Mongolia funded by Gavi. This interest was assessed as non- personal, specific and financially significant\*.

### **Kathleen Neuzil**

- Serves as a member of the Board of Directors for the US National Foundation of Infectious Diseases. This interest was perceived as non-personal, non-specific and financially insignificant\*.
- Served until 2021 as an investigator on a grant from University of Washington for a COVID-19 post-exposure prophylaxis study of hydroxychloroquine. This interest was perceived as non-personal, non-specific and financially significant\*.
- Served until 2022 as co-chair of the National Institutes of Health (NIH) COVID-19 Vaccine Prevention Network, which serves as the focal point for USG sponsored trials in COVID-19 vaccines and monoclonal antibodies. This Network is supported through an NIH grant for the leadership of the Vaccine Treatment and Evaluation Units. This interest was perceived as non-personal, non-specific and financially significant\*.
- Served until 2023 as principal investigator for the NIH funded NIH T32 Fellowship Training Program in Vaccinology. This interest was perceived as non-personal, non-specific and financially significant\*.
- Served until May 2024 as PI for NIH-funded Collaborative Influenza Vaccine Innovation Center (CIVICs) program. This interest was perceived as non-personal, non-specific and financially significant\*.



- Served until May 2024 as principal investigator for the National Institute of Allergy and Infectious Diseases (NIAID) /NIH funded Advanced Development of a Multivalent Vaccine Candidate for Filovirus and Lassa Fever. This interest was perceived as non-personal, non-specific and financially significant\*.
- Served until May 2024 as principal investigator for the BMGF-funded Typhoid Vaccine Acceleration Consortium (2016-2021 and extension 2021-2025), which includes clinical studies of Bharat Biotech, India Typhbar-TCV. This interest was perceived as non-personal, non-specific and financially significant\*.
- Served until May 2024 as a principal investigator for the Vaccine Company, Inc. funded “A Phase 1, Open-label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of DCFHP-Alum, A Spike-Functionalized Ferritin Nanoparticle Vaccine Targeting COVID-19, Col-formulated with Aluminum Hydroxide Adjuvant, in Healthy Adults in the United States”. This interest was perceived as non-personal, non-specific and financially insignificant\*.
- Her previous institution received research support for the following studies, however she no longer serves there and ended on May 2024. These interests were perceived as non-personal, non-specific and financially significant\*.
  - Safety and reactogenicity of Hantaan virus (HTNV) and Puumala virus (PUUV), and combination HTNV/PUUV DNA vaccine from Geneva Foundation.
  - Double-blind, Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety, Tolerability, Efficacy, and Immunogenicity of a 2-Dose and 3-Dose Regimen of V160, Human Cytomegalovirus (HCMC) Vaccine in Healthy Seronegative Adolescent and Adult Women 16-35 Years of Age funded by Merck.
  - Longitudinal Antibody Profile Correlated with Protection from Malaria in Malawi – Sponsor - Boston University.
  - DON in Pediatric Cerebral Malaria: A Phase 1 Dose-Escalation Safety Study – Sponsor- Children’s Research Institute/NIH.
  - Vaccine Treatment Evaluation Unit (VTEU) Clinical Site: DMID 19-0007; Exposure-Response Evaluation of IV Artesunate in Children with Severe Malaria – Sponsor – NIAID/NIH.
  - VTEU 13-0088: A Phase 1 Challenge Study to Evaluate Safety, Immunogenicity, and Efficacy of a Malaria Vaccine (rCSP adjuvanted with AP 10-602 [GLA-LSQ]), in Healthy Adults – Sponsor – NIAID/NIH.

- Dose Escalation Study Of Sanaria's Irradiated Sporozoite Vaccine (PfSPZ Vaccine), Followed By A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial to Evaluate The Safety And Immunogenicity Of PfSPZ Vaccine in Malaria-Experienced Adults in Burkina Faso – Sponsor – NIAID/NIH.
- Development of Malaria Vaccine Candidate VLPM01, Phase 2 – Sponsor – Maryland Industrial Partnerships (MIPS).
- Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease Vaccine – Sponsor – Seek, UK.
- “An exploratory Phase I, randomized, observer-blind, placebo-controlled dose escalation trial evaluating the safety, tolerability and exploratory immunogenicity of an investigational RNA-based vaccine for active immunization against malaria” – Sponsor - BioNTech SE.

### **Carla Vizzotti**

- Serves as a member of Global Advisory Group of Experts (GAGE) of the International Vaccine Institute (IVI) This interest was perceived as non-personal, non-specific and financially insignificant\*.Serves as member of the World Health Summit Council. This interest was perceived as non-personal, non-specific and financially insignificant\*..
- Served as a lead until 2024 on the Health Policy and Equity Innovation Hub at the National University of San Martín, through which the advisory support to Lab Cassará regarding the ARVAC vaccine was conducted. This interest was perceived as non-personal, non-specific and financially significant\*.
- Serves as an advisor on a collaborative study on ITrials of RSV vaccine effectiveness funded by Pfizer. This interest was perceived as non-personal, non-specific and financially significant\*.
- Serves as a Secretary on the Board of Directors of the Argentine Society of Vaccinology and Epidemiology, funded by six laboratories and Pfizer. This interest was perceived as non-personal, non-specific and financially insignificant\*.

Participated at the HPV Summit, funded by MSD, This interest was perceived as non-personal, non-specific and financially insignificant\*.

## **Hanna Nohynek**

- Serves as member to DSMB of COMCov studies of University of Oxford. This interest was assessed as non-personal, non-specific and financially insignificant\*.
- Serves as member to DSMB of the VACCCELERATE cologne university on COVID-19 vaccines immunogenicity and safety. This interest was assessed as non-personal, non-specific and financially insignificant\*.
- Her institution (Finnish Institute for Health and Welfare) had received research grants from vaccine manufacturers for phase III and IV studies of influenza vaccines until 2021. This interest was assessed as non-personal, non-specific and financially significant\*.
- Serves as member of the Finnish Institute for Health and Welfare (THL) NITAG. This interest was perceived as non-personal, non-specific and financially insignificant\*.
- Serves as chief physician in charge of advising the Finnish Ministry of Health on vaccines. This interest was perceived as non-personal, non-specific, and financially insignificant\*.
- Served until 2021 as Chair of the DSMB of an IMI funded PERISCOPE study on maternal pertussis immunization in the Gambia. This interest was perceived as non-personal, non-specific and financially insignificant. \*
- Serves as a member of the EMA-ECDC funded Vaccine Monitoring Platform since December 2022. This interest was perceived as non-personal, non-specific and financially insignificant\*.
- Served until 2022 as investigator in an Innovative Medicines Initiative (IMI) funded project DRIVE (Development of Robust and Innovative Vaccine Effectiveness) 2018-23 for influenza vaccine. This interest was perceived as non-personal, non-specific and financially insignificant\*.
- Serves as a member of the European Centre for Disease Prevention and Control (ECDC) coordinated NITAG network Scientific committee. This interest was perceived as non-personal, non-specific and financially insignificant\*.
- Serves in the Scientific Advisory Group of European Medical Agency on vaccines related matters, Board of Trustees of the International Vaccine Institute, and Board of Trustees of the icddr.b and Steering Group of the Vaccine Monitoring Platform of the European Medical Agency (EMA) and ECDC. This interest was perceived as non-personal, non-specific and financially insignificant\*.

- Serves as principal investigator on the Zoonotic Influenza Vaccine Seqirus immunogenicity and Safety study funded by Institute THL. This interest was perceived as non-personal, non-specific, and financially significant.
- Serves as principal investigator on immunogenicity of COVID-19 vaccines, funded by Finnish institute of health and welfare. This interest was perceived as non-personal, non-specific and financially in significant\*.
- Served as a member in the PROMISE consortium to develop protocols for phase IV studies on RSV vaccines and monoclonal antibodies until 2024. This interest was perceived as non-personal, non-specific and financially insignificant.

### **Punnee Pitisuttithum**

- Serves as a committee member on the Meta DSMB, CEPI. This interest was perceived as non-personal, non-specific and financially insignificant\*.
- Serves as a committee member on the Advisory Committee on Immunization Practices, National Vaccine Institute, Thailand. This interest was perceived as non-personal, non-specific and financially insignificant\*.
- Serves as principal investigator for IVI funded trial “Phase II/III To Evaluate Safety And Immunogenicity of 2 Dose-Regimen Of BBV87 Chikungunya Vaccine In Healthy Subjects Aged 12 to 65 years”. This interest was perceived as non-personal, non-specific and financially significant\*.
- Serves as principal investigator for Merck funded A phase 3, International, Multi-center, Randomized, Double-blind, Placebo- controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent with HPV Types 16, 18, 31, 33, 45, 52 or 5E in adult males, 20 to 45 lvears of age. This interest was perceived as non-personal, non-specific and financially significant\*.
- Serves as a member on the Safety Monitoring Committee for the U.S. Military HIV Research Program (MHRP). This interest was perceived as non-personal, non-specific and financially significant\*.
- Serves as project chair for the government-funded (national research council) “Effectiveness of single dose or two doses of HPV vaccine among adolescents and reproductive women: A test-negative control study”. This interest was perceived as non-personal, specific and financially significant\*.
- Serves as project chair for the government-funded (national research council) Effectiveness of the 13- Valent Pneumococcal Conjugated Vaccine Against

Community- Acquired Pneumonia in Older Thai Adults: A Matched Case-Control Study. This interest was perceived as non- personal, specific and financially significant\*

- Serves as project chair for the government-funded (national research council) Evaluation of Interferon- gamma release assays symptom screening and chest radiograph for Detection of Subclinical Tuberculosis of End-stage Kidney Disease and Kidney Transplant Recipients in Thailand. This interest was perceived as non-personal, specific and financially significant\*
- Serves as project chair/CRS leader for the DAIIDS funded phase I clinical trial to evaluate the safety and immunogenicity of CH505M5 N197D mRNA-gp160 followed by CH505 TF mRNA-gp160 in adults in overall good health without HIV. This interest was perceived as non-personal, specific and financially significant\*
- Serves as project chair/CRS leader for HVTN FUNDED A Phase 2a/2b Randomized, Placebo-Controlled Study Evaluating Safety, Immunogenicity, and Therapeutic Efficacy of ID93 + GLA-SE Vaccination in Participants with Rifampicin-Susceptible Pulmonary TB. This interest was perceived as non-personal, specific and financially significant\*
- Served until 2023 as principal investigator for the GPO-funded phase III to “Evaluate the Immunogenicity and Safety of Tri Fluvac influenza vaccine”. This interest was perceived as non-personal, non-specific and financially significant\*.
- Served until 2023 as principal investigator for the National Science and Technology Development Agency-funded phase II/III combined Diphtheria-Tetanus-recombinant acellular pertussis (DTaP) vaccine to a licensed DTaP based vaccine. This interest was perceived as non-personal, non-specific and financially significant\*.
- Served until 2023 as principal investigator coordinator for the government funded study of the immunogenicity and safety of the 3<sup>rd</sup> dose of the ChAdOx-nCoV19 or BNT162b2 vaccine against COVID-19. This interest was perceived as non personal, specific and financially insignificant\*.
- Served until 2023 as principal investigator for the Janssen funded phase I/II study of the immunogenicity and safety of the Ad26.CoV2.S heterologous vaccine against COVID-19. This interest was perceived as non-personal, specific and financially significant\*.

- Served as principal investigator for the GPO funded phase I/II study of the NDV-HXP-S COVID-19 vaccine until 2023. This interest was perceived as non-personal, specific and financially significant\*.

### **Anthony Scott**

- Served as the DSMB member at PATH Vaccine Solutions, clinical development of Pneumosil vaccine trial in The Gambia until 2020. This interest was assessed as non-personal, non-specific and financially insignificant\*.
- Served as a consultant on WHO working group on Vaccines and Antimicrobial Resistance (AMR) until 2021. This interest was assessed as non-personal, non-specific and financially insignificant\*.
- Serves as the DSMB member at Iliad Biotechnologies, Phase 2b trial of Intranasal Pertussis vaccine BPZE1. This interest was assessed as non-personal, non-specific and financially insignificant\*.
- Serves on the United Kingdom (UK) Department of Health and Social Care Joint Committee on Vaccination and Immunisation. This interest was assessed as non-personal, non-specific and financially insignificant\*.
- Served on the United Kingdom (UK) commission on human medicine, expert working group on COVID-19 vaccine safety until 2022. This interest was assessed as non-personal, non-specific and financially insignificant\*.
- Serves as principal investigator for the BMGF funded study on fractional doses of PCV in infants in Kenya. This interest was perceived as non-personal, specific and financially significant\*.
- Served as co-investigator for the UK Foreign Commonwealth and development office funded study on COVID-19 vaccine evaluation in Kenya until 2022. This interest was perceived as non-personal, specific and financially significant\*.
- Serves coinvestigator for the European Union funded study on Vacc-iNTS, Phase I/II trial of NTS vaccine in Kenyan adults. This interest was perceived as non-personal, non-specific and financially significant\*.
- Served as principal investigator for the Gavi funded study on the Pneumococcal Conjugate Vaccine Impact Study (PCVIS), a-post-licensure study of PCV10 impact in Kenya, until 2022. This interest was perceived as non-personal, specific and financially significant\*.
- Serves as principal investigator for a non-trial vaccine research grant in the health protection research unit in immunization, funded by the national institute

of health research, UK. This interest was perceived as non-personal, non-specific and financially significant\*

- Received travel grant for organizing ISPPD Toronto in 2022. This interest was perceived as non-personal, non-specific and financially insignificant\*
- His institution receives research support for the following studies. These interests were perceived as non-personal, specific and financially significant\*
  - Research grant on cause of child death in Ethiopia (CHAMPS) from Emory University.
  - Research grant on surveillance of Meningococcus in Ethiopia from BMGF.
  - Research grant on using pneumococcal carriage to inform PCV policy in Africa from Wellcome Trust.
  - Research grant on developing vaccine policy within the UK from National Institute for Health Research.

### **Ghassan Dbaibo**

- Serves as a member of the advisory board of COVID-19 vaccines in pediatric-Pfizer. This interest was perceived as non-personal, non-specific, and financially insignificant\*.
- Serves as a member of the Pneumococcal vaccine advisory board —pediatric MSD. This interest was perceived as non-personal, specific, and financially insignificant\*.
- Serves as principal Investigator for meningococcal conjugate vaccine in elderly, funded by Sanofi. This interest was perceived as non-personal, non-specific and financially significant\*

\* According to WHO's Guidelines for Declaration of Interests (WHO expert), an interest is considered "personal" if it generates financial or non-financial gain to the expert, such as consulting income or a patent. "Specificity" states whether the declared interest is a subject matter of the meeting or work to be undertaken. An interest has "financial significance" if the honoraria, consultancy fee or other received funding, including those received by expert's organization, from any single vaccine manufacturer or other vaccine-related company exceeds 5,000 USD in a calendar year. Likewise, a shareholding in any one vaccine manufacturer or other vaccine-related company in

excess of 1,000 USD would also constitute a “significant shareholding”. As per the WHO assessment of conflicts of interests, “Institution” relates only to the expert’s research/or work unit as a subdivision of the department. Funding going to the SAGE member’s research unit needs to be declared.

The above-stated SAGE conflicts were made available for public notice and comment three weeks prior to the SAGE meeting to provide information on interests or biases relating to potential conflicts of SAGE members. No comments were received.